Palatin Technologies to Present at the 36th Annual Canaccord Genuity Growth Conference
CRANBURY, N.J., Aug. 8, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Carl Spana, the Company’s President & Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference …
Palatin Technologies to Present at the 36th Annual Canaccord Genuity Growth Conference Read More »